Why EVgo Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
Portfolio Pulse from Lisa Levin
Several stocks experienced significant pre-market trading movements. Adamis Pharmaceuticals Corporation (ADMP) surged 64.6% after pricing its public offering. T2 Biosystems (TTOO) rose 34.2% after receiving an extension to comply with Nasdaq listing requirements. Upwork (UPWK) rose 17.1% after posting upbeat Q2 results and raising full-year guidance. EVgo (EVGO) gained 15.3% after reporting better-than-expected Q2 results and announcing a leadership succession plan. On the downside, Aravive (ARAV) fell 50.8% after its Phase 3 study did not meet the primary endpoint. DXC Technology Company (DXC) fell 19.4% after reporting worse-than-expected Q1 results and issuing a below-consensus outlook.
August 04, 2023 | 1:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Adamis Pharmaceuticals surged 64.6% after pricing its public offering.
The surge in ADMP's stock price is likely due to the pricing of its public offering, which may have been viewed favorably by investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
EVgo gained 15.3% after reporting better-than-expected Q2 results and announcing a leadership succession plan.
The gain in EVGO's stock price is likely due to its better-than-expected Q2 results and the announcement of a leadership succession plan, which may have been viewed favorably by investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
T2 Biosystems rose 34.2% after receiving an extension to comply with Nasdaq listing requirements.
The rise in TTOO's stock price is likely due to the extension it received to comply with Nasdaq listing requirements, which may have eased investor concerns.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Upwork rose 17.1% after posting upbeat Q2 results and raising full-year guidance.
The rise in UPWK's stock price is likely due to its positive Q2 results and raised full-year guidance, which may have been viewed favorably by investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Aravive fell 50.8% after its Phase 3 study did not meet the primary endpoint.
The fall in ARAV's stock price is likely due to its Phase 3 study not meeting the primary endpoint, which may have been viewed negatively by investors.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
NEGATIVE IMPACT
DXC Technology Company fell 19.4% after reporting worse-than-expected Q1 results and issuing a below-consensus outlook.
The fall in DXC's stock price is likely due to its worse-than-expected Q1 results and below-consensus outlook, which may have been viewed negatively by investors.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100